Risk of Second Primary Lung Cancer in Patients with Thyroid Cancer: a Meta-analysis Based on Big Population Studies

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2023 Apr 13

PMID 37052139

Authors

Haoyu Wang

Yan Wang

Ruiyuan Yang

Dan Liu

Weimin Li

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death. Therefore, we aimed to investigate the risk of second primary lung cancer (SPLC) in patients with thyroid cancer.

Methods: We searched the PubMed, Web of Science, Embase, and Scopus databases up to November 24, 2021, for relevant research and merged the standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs) to evaluate the risk of developing SPLC in patients with thyroid cancer.

Results: Fourteen studies involving 1,480,816 cases were included in our meta-analysis. The pooled result demonstrated that thyroid cancer patients may have a higher risk of SPLC than the general population (SIR = 1.21, 95% CI: 1.07-1.36, P < 0.01, I2 = 81%, P < 0.01). Subgroup analysis stratified by sex indicated that female patients may have a markedly higher risk of SPLC than male patients (SIR = 1.65, 95% CI: 1.40-1.94, P < 0.01, I2 = 75%, P < 0.01).

Conclusions: Thyroid cancer patients are more likely to develop SPLC than the general population, especially women. However, other risk factors must be investigated, and more prospective studies are needed to confirm our results.

Registration: International Prospective Register of Systematic Reviews: No. CRD42021285399.

References

Wang T, Sosa J . Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol. 2018; 14(11):670-683. DOI: 10.1038/s41574-018-0080-7. View

Chuang S, Hashibe M, Yu G, Le A, Cao W, Hurwitz E . Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett. 2005; 238(1):42-52. DOI: 10.1016/j.canlet.2005.06.015. View

Kim J, Gosnell J, Roman S . Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2019; 16(1):17-29. DOI: 10.1038/s41574-019-0263-x. View

Subbiah V, Gainor J, Rahal R, Brubaker J, Kim J, Maynard M . Precision Targeted Therapy with BLU-667 for -Driven Cancers. Cancer Discov. 2018; 8(7):836-849. DOI: 10.1158/2159-8290.CD-18-0338. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Yan Y, Fu J, Kowalchuk R, Wright C, Zhang R, Li X . Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review. Transl Lung Cancer Res. 2022; 11(2):307-322. PMC: 8902083. DOI: 10.21037/tlcr-22-108. View

Hanania A, Mainwaring W, Ghebre Y, Hanania N, Ludwig M . Radiation-Induced Lung Injury: Assessment and Management. Chest. 2019; 156(1):150-162. PMC: 8097634. DOI: 10.1016/j.chest.2019.03.033. View

Hsu L, Chu N, Kao S . Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci. 2017; 18(8). PMC: 5578103. DOI: 10.3390/ijms18081713. View

Cho Y, Lim J, Oh C, Ryu J, Jung K, Chung J . Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer. 2014; 121(2):259-68. DOI: 10.1002/cncr.29025. View

10.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

11.

Subramanian S, Goldstein D, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I . Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007; 17(12):1277-88. DOI: 10.1089/thy.2007.0171. View

12.

La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F . Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2014; 136(9):2187-95. DOI: 10.1002/ijc.29251. View

13.

Wang H, Li C, Yang R, Jin J, Liu D, Li W . Prognostic Value of the Geriatric Nutritional Risk Index in Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. Front Oncol. 2022; 11:794862. PMC: 8804216. DOI: 10.3389/fonc.2021.794862. View

14.

Ho J, Kim E, Han M, Jung I, Lee J, Jo Y . Impact of Dyslipidemia on the Risk of Second Cancer in Thyroid Cancer Patients: A Korean National Cohort Study. Ann Surg Oncol. 2021; 28(8):4373-4384. DOI: 10.1245/s10434-020-09570-8. View

15.

Ronckers C, McCarron P, Ron E . Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005; 117(2):281-8. DOI: 10.1002/ijc.21064. View

16.

Yu C, Saeed O, Goldberg A, Farooq S, Fazelzad R, Goldstein D . A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. Thyroid. 2018; 28(12):1662-1673. DOI: 10.1089/thy.2018.0244. View

17.

Teng C, Hu Y, Chen S, Yeh C, Chiang H, Chen T . Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. J Natl Cancer Inst. 2015; 108(2). DOI: 10.1093/jnci/djv314. View

18.

Berthe E, Henry-Amar M, Michels J, Rame J, Berthet P, Babin E . Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2004; 31(5):685-91. DOI: 10.1007/s00259-003-1448-y. View

19.

Izkhakov E, Barchana M, Liphshitz I, Silverman B, Stern N, Keinan-Boker L . Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel. Thyroid. 2017; 27(6):793-801. DOI: 10.1089/thy.2016.0481. View

20.

Subbiah V, Shen T, Terzyan S, Liu X, Hu X, Patel K . Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2020; 32(2):261-268. PMC: 7883646. DOI: 10.1016/j.annonc.2020.10.599. View